ReviewModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022
Lung neuroendocrine neoplasms: recent progress and persistent challenges.
Review in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05257551 (Tempus SCLC Observational Study), which is not on this map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Who cites it
113 citing papers in PubMed, 184 citations in OpenAlex.
- Review
- Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors.Thoracic cancer · 2026Review
- Establishment and characterization of TRI-LC21: a novel patient-derived cell line of SMARCA4-deficient undifferentiated thoracic tumor.Human cell · 2026Article
- Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor.Discover oncology · 2026Article
- Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Morphology first: preserving diagnostic hierarchies in high-grade neuroendocrine neoplasms across organ sites.Endocrine · 2026Article
- Correlation of TP53 Mutations With p53 Expression and Ki-67 Index in Pulmonary Large Cell Neuroendocrine Carcinomas.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Identification of Actionable Gene Variants in Pulmonary Large-Cell Neuroendocrine Carcinoma: A Real-World Analysis of a Polish Cohort.International journal of molecular sciences · 2026Article
- Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC).NPJ precision oncology · 2026Article
- Integrative multi-omics profiling deciphers tumor microenvironment heterogeneity and immunotherapy vulnerabilities in lung neuroendocrine carcinomas.Journal of advanced research · 2026Article
- Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence Study.Journal of neuroendocrinology · 2026Article
- Case Report: Synaptophysin-positive SMARCA4-deficient undifferentiated thoracic tumour: a diagnostic pitfall with therapeutic implications.Frontiers in oncology · 2026Article
- Rethinking the prognostic and biological significance of neuroendocrine marker expression in colorectal carcinoma.Frontiers in endocrinology · 2026Article
- A rare incidence of primary pulmonary undifferentiated pleomorphic sarcoma detected as an endobronchial mass and treated by bronchoscopic resection: a case report and literature review.Frontiers in oncology · 2026Article
- Synchronous lung adenocarcinoma and pulmonary carcinoid tumorlets in different lobes: a case report.Frontiers in oncology · 2026Article
- MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives.Virchows Archiv : an international journal of pathology · 2026Review
- Surgical resection reveals combined small-cell lung carcinoma and adenocarcinoma with dual epidermal growth factor receptor and anaplastic lymphoma kinase alterations following neoadjuvant chemotherapy: A rare case.SAGE open medical case reports · 2026Article
- Case Report: Neuroendocrine-marker-negative high-grade neuroendocrine carcinoma mimicking squamous cell carcinoma: an underrecognized diagnostic pitfall.Frontiers in immunology · 2026Article
- Lobar versus sub-lobar resection for clinical stage IA (≤ 2 cm) lung neuroendocrine tumor with spread through air spaces: a multi-center study.Updates in surgery · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
This review summarizes key recent developments relevant to the pathologic diagnosis of lung neuroendocrine neoplasms, including carcinoids, small cell lung carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC). Covered are recent insights into the biological subtypes within each main tumor type, progress in pathological diagnosis and immunohistochemical markers, and persistent challenging areas. Highlighted topics include highly proliferative carcinoids and their distinction from small cell and large cell neuroendocrine carcinomas (NECs), the evolving role of Ki67, the update on the differential diagnosis of NEC to include thoracic SMARCA4-deficient undifferentiated tumors, the recent data on SCLC transcriptional subtypes with the emergence of POU2F3 as a novel marker for the diagnosis of SCLC with low/negative expression of standard neuroendocrine markers, and the update on the diagnosis of LCNEC, particularly in biopsies. There has been remarkable recent progress in the understanding of the genetic and expression-based profiles within each type of lung neuroendocrine neoplasm, and it is hoped that these insights will enable the development of novel diagnostic, prognostic, and predictive biomarkers to aid in the pathologic assessment of these tumors in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.